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Management and treatment outcomes of patients enrolled  
in MDR-TB treatment in Viet Nam
N. T. M. Phuong,1 N. V. Nhung,1 N. B. Hoa,1,2 H. T. Thuy,1 K. C. Takarinda,2 K. Tayler-Smith,3  
A. D. Harries2,4
Tuberculosis (TB) remains one of the most highly prevalent infectious diseases worldwide, with 
high mortality and morbidity. The emergence of 
drug-resistant TB has threatened global efforts to elim-
inate the disease.1 Viet Nam is a high TB burden coun-
try, with associated high rates of multidrug-resistant 
TB (MDR-TB, defined as TB resistant to at least both 
isoniazid [INH] and rifampicin [RMP]). In 2013, of an 
estimated 130 000 new TB cases nationally, 102 196 
were notified.1 The Fourth National Drug Resistance 
Survey (DRS) in 2011 showed an MDR-TB rate of 4% 
among new cases and 23% among retreatment cases.2 
Applying the DRS rates to all notified TB cases in 2013, 
the number of MDR-TB cases was estimated at 5100 
per year.1
With support from the Global Fund (Geneva, 
Switzerland), the Viet Nam National TB Control 
Programme (NTP) implemented Programmatic Man-
agement of Drug-resistant TB (PMDT) in 2009 to de-
tect and enrol MDR-TB patients for treatment with 
quality-assured second-line drugs (SLDs) provided 
through the Green Light Committee mechanism of 
the World Health Organization (WHO) and the Stop 
TB Partnership.3 Following WHO and national 
guidelines, a standardised Category IV regimen was 
indicated for those diagnosed with MDR-TB (Table 
1).4,5 For the first 101 patients enrolled in PMDT in 
2009 at one treatment centre only, treatment out-
comes were promising, with 73% treatment success 
(source: Viet Nam NTP Report), substantially higher 
than that achieved globally during the same 
period.1
Since the pilot study in 2009, PMDT has been 
scaled up rapidly in Viet Nam. However, no formal 
detailed evaluation has been undertaken of PMDT 
performance and treatment outcomes to assess 
whether the initial high success rate of the pilot 
study has been achieved on a larger scale and under 
routine programme conditions. Such an evaluation 
could help guide the NTP to further improve 
MDR-TB care and treatment in Viet Nam. The find-
ings from the evaluation might potentially be useful 
for other countries attempting to reach the Global 
Plan target of at least 75% MDR-TB treatment 
success.1
The aim of this study was therefore to evaluate 
treatment outcomes and related factors in patients 
enrolled in PMDT in Viet Nam. The first objective 
was to document the annual numbers of patients 
enrolled in Category IV treatment at the national 
level during 2010–2014. Other objectives were to 
determine, among all patients enrolled for Category 
IV treatment during 2010–2012, 1) their demo-
graphic and clinical characteristics, 2) Mycobacte-
rium tuberculosis culture results at 6 months after 
starting treatment, and 3) end-of-treatment out-
comes and factors associated with an unfavourable 
treatment outcome.
METHODS
Study design
This was a retrospective cohort study using national 
reports and record reviews.
General setting
Viet Nam is a South-East Asian country with a popula-
tion of 91.6 million and a gross national income of 
US$5030 per capita.6 TB is a major public health prob-
lem in Viet Nam, which is one of the world’s 22 
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Setting: The programmatic management of drug-resis-
tant tuberculosis (TB) in Viet Nam has been rapidly scaled 
up since 2009.
Objectives: To document the annual numbers of pa-
tients enrolled for multidrug-resistant tuberculosis 
(MDR-TB) treatment during 2010–2014 and to deter-
mine characteristics and treatment outcomes of patients 
initiating treatment during 2010–2012.
Design: A retrospective cohort study using national re-
ports and data from the national electronic data system 
for drug-resistant TB.
Results: The number of patients enrolled annually for 
MDR-TB treatment increased from 97 in 2010 to 1522 in 
2014. The majority of patients were middle-aged men 
who had pulmonary disease and had failed a retreatment 
regimen; 77% had received 2 courses of TB treatment. 
Favourable outcomes (cured and treatment completed) 
were attained in 73% of patients. Unfavourable out-
comes included loss to follow-up (12.5%), death (8%) 
and failure (6.3%). Having had 2 previous treatment 
courses and being human immunodeficiency virus-posi-
tive were associated with unfavourable outcomes.
Conclusion: Increasing numbers of patients are being 
treated for MDR-TB each year with good treatment out-
comes under national programme management in Viet 
Nam. However, there is a need to increase case detec-
tion—currently at 30% of the estimated 5100 MDR-TB 
cases per year, reduce adverse outcomes and improve 
monitoring and evaluation.
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high-burden countries for TB and one of the 27 
high-burden MDR-TB countries.1 Within the NTP, TB 
diagnosis and treatment services are free of charge, in-
cluding for MDR-TB.7
Programme management of TB and MDR-TB
TB control based on the Stop TB strategy has been im-
plemented throughout Viet Nam since 1995, with case 
finding, registration, standardised treatment and mon-
itoring and evaluation carried out in accordance with 
WHO guidelines.7,8 The programme is structured and 
organised through several levels: central, provincial, 
district and commune. Specific health care personnel 
are responsible for TB control at each level.7
To tackle the problem of emergent MDR-TB, PMDT 
was initiated in Viet Nam in 2009 at a single treatment 
centre. By the end of 2014, PMDT had expanded to 10 
main treatment centres covering 41 of the 63 prov-
inces and about 80% of the national population. The 
number of provinces providing MDR-TB services ex-
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TABLE 1 Definitions for the programmatic management of MDR-TB in Viet Nam4,5
Term Definition
Patient registration group
 New A patient who has received none or 1 month of anti-tuberculosis treatment
 Relapse A patient whose most recent treatment outcome was ‘cured’ or ‘treatment completed’ 
and who is subsequently diagnosed with bacteriologically-positive TB by sputum 
smear microscopy or culture
 Treatment after default A patient who returns to treatment bacteriologically positive by sputum smear 
microscopy or culture, following interruption of treatment for 2 consecutive 
months
 Treatment after failure of Category I A patient who has received Category I treatment for TB and in whom treatment has 
failed. Failure is defined as sputum smear-positive at 5 months or later during 
treatment
 Treatment after failure of Category II A patient who has received Category II treatment for TB and in whom treatment has 
failed. Failure is defined as sputum smear-positive at 5 months or later during 
treatment
 Transfer in A patient who has transferred in from another register for treatment of DR-TB to 
continue Category IV treatment
 Other Patients who may not fit into any of the above categories, including the following: 
sputum smear-positive patients with unknown previous treatment outcome; sputum 
smear-positive patients who received treatment other than Category I or II (possibly 
in the private sector); chronic patients who have lived with active TB disease with no 
or inadequate treatment for a period of time until Category IV treatment became 
available
Category IV treatment regimen According to national PMDT guidelines (2009), the following standardised Category 
IV regimen is indicated for patients diagnosed with MDR-TB (by DST or LPA) or 
RR-TB confirmed by Xpert® MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) and 
enrolled in PMDT with total treatment duration of 18–24 months. The drugs in the 
intensive phase (at least 6 months) include: kanamycin (capreomycin), levofloxacin, 
prothionamide, cycloserine (para-amino salicylic acid), ethambutol and 
pyrazinamide; the drugs in the continuation phase (at least 12 months) include: 
levofloxacin, prothionamide, cycloserine (para-amino salicylic acid), ethambutol and 
pyrazinamide
Category IV treatment outcomes
 Cured A Category IV patient who has completed treatment according to the programme 
protocol and has at least 5 consecutive negative cultures from samples collected at 
least 30 days apart in the final 12 months of treatment. If only one positive culture is 
reported during that time, and there is no concomitant clinical evidence of 
deterioration, a patient may still be considered cured, provided that this positive 
culture is followed by a minimum of three consecutive negative cultures taken at 
least 30 days apart
 Treatment completed A Category IV patient who has completed treatment according to the programme 
protocol but does not meet the definition for cure because of lack of bacteriological 
results (i.e., 5 cultures were performed in the final 12 months of treatment)
 Died A Category IV patient who dies for any reason during the course of MDR-TB treatment
 Failed Treatment will be considered to have failed if two or more of the five cultures recorded 
in the final 12 months of therapy are positive, or if any one of the final three cultures 
is positive. (Treatment will also be considered to have failed if a clinical decision has 
been made to terminate treatment early due to poor clinical or radiological 
response or adverse events)
 Defaulted A Category IV patient whose treatment was interrupted for 2 consecutive months for 
any reason without medical approval
 Transferred out A Category IV patient who has been transferred to another reporting and recording 
unit and for whom the treatment outcome is unknown
MDR-TB = multidrug-resistant tuberculosis; TB = tuberculosis; DR-TB = drug-resistant TB; PMDT = programmatic management of drug-resistant 
tuberculosis; DST = drug susceptibility testing; LPA = line probe assay; RR-TB = rifampicin-resistant tuberculosis.
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panded to 6 by 2010, to 20 by 2011, to 35 in 2012–2013, and to 
41 by 2014. By this time, approximately 4000 patients had been 
cumulatively enrolled in MDR-TB treatment. The national policy 
for MDR-TB diagnosis among patients with suspected MDR-TB 
(treatment failure, relapse and loss to follow-up [LTFU] among 
previously treated cases) was initially based on traditional culture 
and drug susceptibility testing (DST) and the line probe assay 
(LPA). However, at the end of 2012, a national decision was made 
to use and scale up the Xpert® MTB/RIF (Cepheid Inc, Sunnyvale, 
CA, USA) assay as the first-line investigation for identifying 
RMP-resistant TB (RR-TB). Once diagnosed, patients with drug-re-
sistant TB (including MDR-TB confirmed by DST or LPA and RR-TB 
confirmed by Xpert) are registered in PMDT and started on Cate-
gory IV treatment according to WHO and national PMDT guide-
lines.4,5 Patients were also assessed for resistance to SLDs on an ad 
hoc basis if they had previously been treated with SLDs or had 
been contacts of patients with extensively drug-resistant TB.
The definitions of the patients’ registration groups, the Cate-
gory IV treatment regimen and treatment outcomes are shown in 
Table 1. Monitoring and evaluation is performed through stan-
dardised paper-based and electronic recording and reporting sys-
tems. eTB Manager, the Viet Nam national electronic data system 
for drug-resistant TB, is used as the data source at the NTP’s Cen-
tral Unit.
Study settings
In addition to the 10 MDR-TB treatment centres established 
throughout the country, 19 treatment sites and 12 satellite sites 
were also established and linked to these centres so that PMDT 
services could be decentralised. The satellite sites refer patients 
with suspected MDR-TB to the centres or treatment sites and pro-
vide follow-up treatment for patients with confirmed MDR-TB 
and RR-TB.
Study population
The study included all patients enrolled for Category IV treat-
ment under PMDT in Viet Nam from 1 January 2010 to 31 De-
cember 2014, and the characteristics and treatment outcomes of 
those enrolled between 2010 and 2012.
Data collection
Aggregate data from the national quarterly reports were used to 
derive the numbers of cases enrolled for Category IV treatment 
from 2010 to 2014. For those enrolled between 2010 and 2012, 
patient characteristics and treatment outcomes included patient 
age, sex, registration group, site of disease, number of previous 
courses of TB treatment, method of diagnosis, DST results, hu-
man immunodeficiency virus (HIV) status, sputum culture re-
sults at baseline and 6 months after treatment initiation and 
treatment outcomes (Table 2). Based on the WHO and national 
guidelines, Category IV treatment outcomes were further 
grouped as favourable (cured or treatment completed) or unfa-
vourable (failed, died, LTFU or transferred out).9 All data were 
retrieved from the Viet Nam eTB Manager at the NTP Central 
Unit.
Data analyses
The data used in the study were collected between January and 
March 2015 and single-entered into EpiData, version 3.1 (EpiData 
Association, Odense, Denmark). Frequencies and proportions 
were used to summarise categorical variables and medians and in-
terquartile ranges were used to summarise continuous variables. 
The χ² test (and χ² test for trend) was used to assess significant as-
sociations between exposure and outcome variables. Unadjusted 
TABLE 2 Characteristics of all patients enrolled for MDR-TB 
treatment in PMDT, Viet Nam, 2010–2012
Baseline characteristics n (%)
Total, n 1380 
Sex
 Male 1074 (78)
 Female 306 (22)
Age (years)
 15–34 380 (28)
 35–54 719 (52)
 55 280 (20)
 Not recorded 1 (1)
Patient registration group*
 New 24 (2)
 Relapse 166 (12)
 Failure Category I 202 (15)
 Failure Category II 891 (65)
 Treatment after LTFU 23 (2)
 Transfer in 6 (1)
 Other 58 (4)
 Not recorded 10 (1)
Site of disease
 Pulmonary 1372 (99)
 Extra-pulmonary 4 (0.5)
 Not recorded 4 (0.5)
Previous courses of TB treatment, n
 1 220 (16)
 2 593 (43)
 3 133 (10)
 4 7 (1)
 Not recorded 427 (31)
Sputum smear diagnosis
 Smear-positive for AFB 1167 (85)
 Smear-negative for AFB 144 (10)
 Smear result not documented 69 (5)
Culture for Mycobacterium tuberculosis
 Culture-positive 923 (67)
 Culture-negative 156 (11)
 Culture result not documented† 301 (22)
Method of MDR-TB diagnosis
 Traditional culture and DST 457 (33)
 LPA 758 (55)
 Xpert® MTB/RIF 164 (12)
 Not recorded 1 (1)
Pattern of drug resistance
 RMP‡ 205 (15)
 RMP, INH 743 (54)
 RMP, INH, EMB 9 (1)
 RMP, INH, SM 114 (8)
 RMP, INH, SM, EMB 207 (15)
 MDR-TB with any SLD resistance 85 (6)
 Not MDR-TB§ 17 (1)
HIV status
 HIV-negative 1161 (84)
 HIV-positive 53 (4)
 HIV status not known 166 (12)
* See Table 1 for definitions.
† Including 203 (15%) cases sputum smear-positive for AFB.
‡ Including patients diagnosed with RMP resistance only by Xpert (n = 164) and 
those diagnosed with RMP monoresistance by culture and DST or LPA (n = 41).
§ Including patients with resistance to other first-line drugs such as INH, EMB and SM 
who did not have MDR-TB.
MDR-TB = multidrug-resistant tuberculosis; PMDT = programmatic management of 
drug-resistant TB; LTFU = loss to follow-up; AFB = acid-fast bacilli; DST = drug sus-
ceptibility testing; LPA = line probe assay; RMP = rifampicin; INH = isoniazid; EMB = 
ethambutol; SM = streptomycin; SLD = second-line drug; HIV = human immunodefi-
ciency virus.
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relative risks (RR) and 95% confidence intervals (CIs) were calcu-
lated to establish measures of association between risk factors and 
treatment outcomes. Levels of significance were set at 5%. Data 
analyses were performed using OpenEpi version 3.03a (Open 
Source Epidemiologic Statistics for Public Health, Atlanta, GA, 
USA).
Ethics approval
This study was approved by the Viet Nam NTP. Ethics approval 
from the Ethics Committee of the Viet Nam National Lung Hospi-
tal (Hanoi, Viet Nam) was not required since the study used routine 
NTP data. Ethics approval for the study was obtained from the Eth-
ics Advisory Group of the International Union Against Tuberculosis 
and Lung Disease, Paris, France. As the study was based on a record 
review, informed consent from patients was not necessary.
RESULTS
Trends and characteristics of patients enrolled for MDR-TB 
treatment
The number of patients enrolled annually for MDR-TB treatment 
in national PMDT in Viet Nam increased from 97 in 2010 to 1522 
in 2014 (Figure).
The characteristics of patients enrolled for MDR-TB treatment 
between 2010 and 2012 are shown in Table 2. The majority of the 
patients were male, and the median age (interquartile range) was 
44 (33–53) years. Most patients had been diagnosed with pulmo-
nary disease; the predominant category was failure of Category II 
retreatment regimen. Information on the number of previous 
courses of TB treatment was available for about 70% of patients; 
77% of these had received 2 previous courses of treatment. 
About 85% of patients were sputum smear-positive for acid-fast 
bacilli and 67% were culture-positive for Mycobacterium tuberculo-
sis. The proportions of patients diagnosed with MDR-TB using 
culture and DST, LPA and Xpert were respectively 33%, 55% and 
12%. There were 1073 (78%) patients with MDR-TB on its own or 
associated with resistance to other first-line anti-tuberculosis 
drugs, 205 (15%) with resistance only confirmed for RMP (due to 
diagnosis by Xpert only or because of true RMP monoresistance) 
and 85 (6%) with additional resistance to one of the SLDs. Seven-
teen patients who did not have MDR-TB but were resistant to 
INH, ethambutol or streptomycin, alone or in combination, were 
placed on Category IV treatment. HIV testing was performed 
among 1214 (88%) patients: of these, 53 (4%) were HIV-infected, 
of whom 25 (47%) were known to be on antiretroviral therapy 
(ART), with or without cotrimoxazole.
Interim outcome at 6 months
Interim outcomes at 6 months for all patients enrolled between 
2010 and 2012 are shown in Table 3. Of the 92% of patients who 
were still receiving MDR-TB treatment at 6 months, approxi-
mately 40% had no recorded sputum culture result. Among the 
713 patients in whom culture had been performed, 94% were cul-
ture negative.
Final treatment outcomes and factors associated with 
unfavourable outcomes
Final treatment outcomes of patients enrolled in each annual co-
hort and in total from 2010 to 2012 are shown in Table 4. For all 
patents combined, a favourable outcome was achieved in 73%. 
The proportion achieving a favourable outcome showed a 
non-significant decrease over the 3 years, from 78% in 2010 to 
72% in 2012, as the numbers of patients increased (χ² test for 
trend = 1.48, P = 0.22). The most common unfavourable outcome 
was LTFU, followed by death and failure. Table 5 shows factors as-
sociated with an unfavourable outcome. The risk of an unfavour-
able outcome was higher among patients failing Category II treat-
ment (RR 1.1, 95%CI 1.1–1.2) and those with an unknown 
FIGURE Number of patients enrolled for MDR-TB treatment in 
PMDT, Viet Nam, 2010–2014. Category IV = treatment for MDR-TB; 
MDR-TB = multidrug-resistant tuberculosis; PMDT = programmatic 
management of drug-resistant tuberculosis.
TABLE 3 Interim outcomes at 6 months for all patients enrolled for 
MDR-TB treatment in PMDT, Viet Nam, 2010–2012
Interim outcomes at 6 months n (%)
Total 1380 (100)
Patients still receiving MDR-TB treatment at 6 months 1272 (92)
 Culture negative 672 (49)
 Culture positive 41 (2)
 No recorded result 559 (41)
Patients no longer receiving MDR-TB treatment at 6 months 108 (8)
 Died 44 (3)
 LTFU 64 (5)
MDR-TB = multidrug-resistant tuberculosis; PMDT = programmatic management of 
drug-resistant TB; LTFU = loss to follow-up.
TABLE 4 Treatment outcomes for all patients enrolled for MDR-TB 
treatment in PMDT in Viet Nam, 2010–2012
Treatment outcome
2010
n (%)
2011
n (%)
2012
n (%)
Total
n (%)
Total 97 (100) 585 (100) 698 (100) 1380 (100)
Favourable 76 (78) 429 (73) 503 (72) 1008 (73)
 Cured 70 (72) 380 (65) 385 (55) 835 (61)
 Treatment completed 6 (6) 49 (8) 118 (17) 173 (12)
Unfavourable 21 (22) 156 (27) 195 (28) 372 (27)
 Failed 7 (8) 43 (7) 35 (5) 85 (6)
 Died 8 (8) 38 (7) 65 (9) 111 (8)
 LTFU 6 (6) 74 (13) 94 (14) 174 (13)
 Transferred out 0 (0) 1 (1) 1 (1) 2 (1)
MDR-TB = multidrug-resistant tuberculosis; PMTD = programmatic management of 
drug-resistant TB; LTFU = loss to follow-up.
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previous treatment history (RR 3.3, 95%CI 2.1–5.2), compared 
with those having failed Category I treatment. HIV-positive pa-
tients had a higher risk of an unfavourable outcome compared 
with non-HIV-infected patients. In HIV-positive patients, 17 
(61%) of the 28 who were not on ART had an unfavourable out-
come, significantly more than the 6/25 (24%) patients on ART 
(RR 2.5, 95%CI 1.2–5.4, P  0.01) (data not shown in the table).
DISCUSSION
This is the first formal and detailed evaluation on the perfor-
mance and outcomes of expanded PMDT in Viet Nam. Over the 
5-year period from 2010 to 2014, the number of patients enrolled 
for MDR-TB treatment increased considerably. The majority of 
these patients were male and middle-aged, mirroring the general 
sociodemographic characteristics of TB patients in Viet Nam.10 
Many patients had already received 2 previous courses of an-
ti-tuberculosis treatment, and 33% had failed a retreatment regi-
men, indicating a pressing need to identify drug resistance much 
earlier. Nonetheless, treatment outcomes were encouraging. For 
those with documented results, a high proportion had negative 
sputum cultures at 6 months of treatment. The treatment success 
rate of 73% in the combined 2010–2012 cohort is comparable to 
the 2009 pilot study and higher than the global average of 48% 
reported in 2011.11 LTFU was the main unfavourable treatment 
outcome. This could be improved by shortening the length of the 
treatment regimens, which is being assessed in several countries, 
including Viet Nam.12,13 Unsurprisingly, those who failed the re-
treatment regimen, had an unknown history of previous TB treat-
ment, or were HIV-infected and not on ART, had a higher risk of 
an unfavourable outcome.
A major strength of our study is that we used countrywide data 
with large numbers of patients enrolled for anti-tuberculosis treat-
ment. We also followed the STrengthening the Reporting of OB-
servational studies in Epidemiology (STROBE) guidelines and 
sound ethical principles for conducting and reporting in this ob-
servational study.14,15 The main limitation was related to unre-
corded data in the electronic monitoring system, especially on 
the number of patients evaluated at baseline for SLD resistance, 
the use of incentives and enablers, and the sputum culture results 
at baseline and follow-up. This last deficiency compromised our 
ability to evaluate 6-month treatment outcomes in annual co-
horts of patients enrolled for treatment. There was also a discrep-
ancy between the number of patients enrolled for MDR-TB treat-
ment during 2010–2012 in the aggregate quarterly report data 
compared with that in the eTB Manager data; this may have been 
due to differences in dates between registration and start of treat-
ment at the end of the year in the two reporting systems.
Despite the impressive increase in numbers of MDR-TB pa-
tients enrolled each year, in 2014 PMDT had only reached 30% of 
the estimated 5100 MDR-TB patients in the country. Possible rea-
sons for this include the fact that PMDT does not yet have 100% 
countrywide coverage, new TB patients (of whom 4% have 
MDR-TB) are not being prioritised for Xpert screening due to lim-
ited resources, there is insufficient TB screening capacity in pe-
ripheral facilities, and patients diagnosed and managed in the pri-
vate sector are not being reported.16 These deficiencies aside, Viet 
Nam’s PMDT has performed well over the past 5 years in terms of 
expanding service coverage and maintaining high treatment suc-
cess rates, and Viet Nam is one of only five high MDR-TB burden 
countries worldwide to achieve a success rate of 70%.1
In the Western Pacific region, which has a similar MDR-TB epi-
demiology to Viet Nam, the 2011 MDR-TB cohorts achieved a 
treatment success of only 52%.17 Results also vary by country in 
areas outside the Western Pacific region. Both Israel and the Do-
minican Republic, which have low MDR-TB burdens, recently re-
ported treatment success rates of respectively 71% and 74%,18,19 
while South Africa, which has a large MDR-TB burden associated 
with a high prevalence of HIV, achieved a treatment success rate 
of only 44%.20
This study has several programmatic implications. First, Viet 
Nam needs to increase its MDR-TB case detection rate. This will 
be possible once full national coverage of PMDT is achieved, 
which is expected by 2018 given current expansion. Within the 
PMDT, additional resources are also needed to increase drug resis-
tance screening of new patients by traditional culture and DST, 
LPA or Xpert. There is also a need for better collaboration with 
the private sector to ensure that patients outside PMDT are diag-
nosed, treated and evaluated according to standardised guide-
TABLE 5 Risk factors associated with unfavourable treatment 
outcomes in all patients enrolled for MDR-TB treatment in PMDT, 
Viet Nam, 2010–2012
Risk factor n
Unfavourable 
outcome
n (%) RR (95%CI) P value
Sex
 Male 1074 297 (28) 1.0 (reference)
 Female 306 76 (25) 0.89 (0.7–1.1) 0.32
Age (years)*
 15–34 380 95 (25) 1.0 (reference)
 35–54 719 193 (27) 1.03 (0.9–1.1) 0.51
 55 280 84 (30) 1.2 (0.9–1.4) 0.15
Patient registration group†‡
 New 24 8 (33) 1.7 (0.8–3.7) 0.20
 Relapse 166 41 (25) 1.1 (0.8–1.4) 0.51
 Failure Category I 202 44 (22) 1.0 (reference)
 Failure Category II 891 231 (26) 1.1 (1.1–1.2) 0.01
 Treatment after LTFU 23 7 (30) 1.5 (0.6–3.4) 0.35
 Unknown history§ 58 34 (59) 3.3 (2.1–5.2) 0.001
Previous courses of TB 
treatment, n¶
 1 220 51 (23) 1.0 (reference)
 2 593 125 (21) 0.97 (0.9–1.1) 0.52
 3+ 140 44 (31) 1.3 (0.9–1.7) 0.08
Drug resistance patterns
 MDR-TB# 1278 342 (27) 1.0 (reference)
 MDR-TB with known SLD 
resistance 
85 27 (32) 1.3 (0.8–1.9) 0.32
 Not MDR-TB 17 3 (18) 0.6 (0.2–2.0) 0.40
HIV status**
 HIV-negative 1161 299 (26) 1.0 (reference)
 HIV-positive 53 23 (43) 2.1 (1.3–3.6) 0.01
* One missing record.
† See Table 1 for definitions.
‡ 10 missing records and 6 patients belonged to ‘transfer-in’ group.
§ Previous treatment history unknown.
¶ Excluding 427 cases (including new cases and cases with TB treatment history not 
recorded).
# Including all patients with resistance to both RMP and INH.
** Excluding 166 patients with unknown HIV status.
MDR-TB = multidrug-resistant tuberculosis; PMDT = programmatic management of 
drug-resistant TB; RR = relative risk; CI = confidence interval; LTFU = loss to fol-
low-up; SLD = second-line drug; HIV = human immunodeficiency virus.
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lines.21 The current public-private mix initiative for drug-suscepti-
ble TB must also incorporate drug-resistant TB.
Second, there is a need for earlier identification of patients 
with MDR-TB and better knowledge about SLD resistance. Cur-
rently, 33% of MDR-TB patients are diagnosed after two or more 
previous courses of anti-tuberculosis treatment, and this diagnos-
tic delay threatens successful treatment outcomes. Drug resistance 
must be investigated and identified in individuals who have failed 
Category I treatment and/or are still sputum smear-positive at 2 
or 5 months after starting their first course of Category II treat-
ment. Systems for transporting sputum specimens from periph-
eral health facilities to laboratories equipped to diagnose drug re-
sistance often function poorly in low- and middle-income 
countries. Thus, efforts to improve transportation and deal with 
logistical challenges are needed.22–24 Earlier diagnosis of MDR-TB 
should lead to improved treatment outcomes and reduced TB 
transmission in the community.
Resistance to SLDs also worsens treatment outcomes. Viet Nam 
needs to increase its laboratory capacity to measure SLD resis-
tance patterns as a systematic policy rather than performing DST 
only among patients with a previous history of SLD treatment. 
The inclusion of new drugs such as delamanid and bedaquiline in 
more effective regimens also needs to be considered. These mea-
sures should be included in a comprehensive PMDT package to 
ensure quality service as numbers enrolling for treatment increase 
over the years.
Third, HIV is associated with poor treatment outcomes in 
MDR-TB patients, especially in those not on ART. All HIV-infected 
TB patients should start ART and cotrimoxazole as early as possi-
ble, as these interventions improve treatment success and reduce 
mortality.25,26
Finally, more attention needs to be paid to monitoring and 
evaluation and ensuring that all data pertaining to baseline char-
acteristics, follow-up sputum culture results and treatment out-
comes are entered into paper-based registers and electronic data 
systems. In this regard, our study demonstrates the potential ben-
efit of countrywide deployment of an electronic-based monitor-
ing system for MDR-TB. This provides not only real-time case-
based information but also a systematic evaluation of overall 
performance from the NTP perspective.
In conclusion, this study indicates favourable national expan-
sion of the PMDT in Viet Nam, and shows that even as patient 
numbers increase, good treatment outcomes, equal to some of the 
best observed in other programmes around the world, can be 
achieved. There are areas for improvement, and this study has 
identified several, but if tackled well, this should lead to improved 
programme performance.
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Contexte : La prise en charge de la tuberculose (TB) 
pharmacorésistante au Viet Nam a bénéficié d’une accélération 
considérable depuis 2009.
Objectifs : Documenter le nombre annuel de patients enrôlés pour 
un traitement de TB multirésistante (TB-MDR) entre 2010 et 2014, et 
déterminer les caractéristiques et les résultats du traitement des 
patients qui l’out commencé entre 2010 et 2012.
Schéma : Etude rétrospective de cohorte basée sur les rapports 
nationaux et les données du système national de données 
électroniques pour la TB pharmacorésistante.
Résultats : Le nombre de patients enrôlés chaque année pour 
traitement de TB-MDR a augmenté de 97 en 2010 à 1522 en 2014. 
La majorité des patients étaient des hommes d’âge moyen qui 
avaient une atteinte pulmonaire et chez qui un protocole de 
retraitement avait échoué ; 77% d’entre eux avaient reçu au moins 
deux traitements de TB. De bons résultats (guérison et achèvement 
du traitement) ont été obtenus chez 73% des patients. Les résultats 
défavorables incluaient les sujets perdus de vue (12,5%), les décès 
(8%) et les échecs (6,3%). Avoir eu plus de deux traitements 
préalables et être positif pour le virus de l’immunodéficience humaine 
étaient associés à des résultats défavorables.
Conclusion : Un nombre croissant de patients est traité pour TB-MDR 
chaque année dans le cadre du programme national de prise en 
charge au Viet Nam, avec de bons résultats. Cependant, il est 
nécessaire d’augmenter la détection des cas (actuellement seulement 
30% des 5100 cas de TB-MDR estimés par an), de réduire la 
proportion de résultats défavorables et d’améliorer le suivi et 
l’évaluation.
Marco de referencia: Desde el 2009, se ha ampliado rápidamente la 
escala del tratamiento de la tuberculosis (TB) farmacorresistente en el 
marco del programa nacional de Viet Nam.
Objetivos: Documentar el número de pacientes inscritos cada año 
en el tratamiento de la TB multidrogorresistente (TB-MDR) del 
2010 al 2014 y determinar los desenlaces terapéuticos y sus 
características en los pacientes que iniciaron tratamiento del 2010 
al 2012.
Método: Fue este un estudio retrospectivo de cohortes a partir de 
los registros y los datos del sistema electrónico nacional de datos 
sobre la TB farmacorresistente.
Resultados: El número de pacientes incorporados cada año al 
tratamiento de la TB-MDR aumentó de 97 en el 2010 a 1522 en el 
2014. En su mayoría, se trató de hombres de mediana edad con 
afectación pulmonar, en quienes había fracasado una pauta de 
retratamiento y de los cuales el 77% había recibido dos o más ciclos 
de tratamiento antituberculoso. El 73% de pacientes alcanzó 
desenlaces favorables (curación y compleción del tratamiento). Los 
desenlaces desfavorables observados fueron la pérdida durante el 
seguimiento (12,5%), la muerte (8%) y el fracaso terapéutico (6,3%). 
El hecho de haber recibido dos o más ciclos de tratamiento 
antituberculoso y la positividad frente al virus de la inmunodeficiencia 
humana se asociaron con los desenlaces desfavorables.
Conclusión: Cada año, un mayor número de pacientes recibe 
tratamiento por TB-MDR en el marco del programa nacional contra la 
TB y alcanza desenlaces terapéuticos favorables en Viet Nam. Sin 
embargo, es preciso aumentar la detección de casos (que alcanza 
actualmente el 30% de los 5100 casos estimados de TB-MDR por 
año), disminuir los desenlaces desfavorables y mejorar el seguimiento 
y la evaluación.
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